Core Viewpoint - Vireo Growth Inc. is expanding its retail presence in Colorado by acquiring 17 dispensaries from PharmaCann Inc., bringing its total to 41 dispensaries in the state, which strengthens its leadership position in the adult-use retail market [1][2]. Group 1: Transaction Details - The total consideration for the acquisition is approximately $49.0 million, payable in subordinate voting shares at closing, along with the assumption of certain liabilities [2]. - The share consideration will be adjusted based on inventory levels and trade payables of the acquired dispensaries, and will be subject to customary resale restrictions under Canadian securities law [2]. - A Management Services Agreement has been established, allowing one of Vireo's subsidiaries to manage the acquired dispensaries until the closing, pending necessary regulatory approvals [2]. Group 2: Strategic Implications - The CEO of Vireo, John Mazarakis, emphasized that this transaction aligns with the company's strategy of growth through accretive mergers and acquisitions, complementing other recent acquisitions in Colorado [3]. - Vireo was founded in 2014 as a pioneering medical cannabis company, focusing on building a disciplined and execution-oriented platform in the industry [3].

Labor Market Overview - The U.S. labor market showed signs of cooling in November with nonfarm payrolls rising by 64,000, which is only modestly above expectations and weak by historical standards, while the unemployment rate unexpectedly climbed to 4.6% [1] Stock Market Performance - The Dow Jones Industrial Average fell 0.6% to 48,114.26, while the S&P 500 dropped 0.2% to 6,800.26; the Nasdaq rose 0.2% to 23,111.46 [1] Tilray Brands Inc. - Tilray Brands Inc. saw a significant increase of 27.54%, closing at $13.94, after trading between an intraday low of $10.50 and a high of $14.55; the stock remains below its 52-week peak of $23.20 but above its 52-week low of $3.51 [2][3] - The rally was fueled by speculation regarding potential U.S. cannabis reclassification following comments from President Donald Trump and positive remarks from CEO Irwin Simon [3] Pfizer Inc. - Pfizer's stock fell by 3.48% to finish at $25.53, with intraday trading between a low of $24.92 and a high of $26.51; shares are below their 52-week high of $27.69 but above the 52-week low of $20.92 [4][5] - The decline followed a cautious long-term outlook, with a new 2026 forecast indicating slower growth due to fading COVID-19 revenues and potential losses of exclusivity, despite cost-cutting measures and a focused R&D pipeline [5] Netflix Inc. - Netflix Inc. increased by 0.85% to close at $94.57, trading between an intraday low of $93.32 and a high of $94.93; the stock remains below its 52-week high of $134.12 but above its 52-week low of $82.11 [6] - The rise in stock price was attributed to a new podcast partnership with iHeartMedia, which aims to broaden Netflix's audio and content ecosystem [6] Lennar Corporation - Lennar Corporation's stock slipped by 1.80% to settle at $117.57, with intraday trading between a high of $120.82 and a low of $116.70; shares are below their 52-week high of $153.48 but above the 52-week low of $98.42 [7][8] - The company reported fourth-quarter revenue of $9.37 billion, beating estimates, but adjusted earnings of $2.03 per share missed expectations; home sales revenue fell by 7% to $8.9 billion [8] - New orders rose by 18% year over year to 20,018 homes, and deliveries increased by 4% to 23,034, although affordability pressures and weak consumer confidence impacted results [8] Tesla Inc. - Tesla Inc. climbed by 3.07% to close at $489.88, reaching an intraday high of $491.50 and a low of $465.83; shares are at a new 52-week high of $491.50, significantly above the 52-week low of $214.25 [9][10] - The increase was driven by heightened enthusiasm around autonomy, robotics, and software, with a surge in interest in its robotaxi program and Optimus humanoid robots, alongside bullish commentary from analysts [10]

Core Viewpoint - President Trump's consideration of reclassifying marijuana as a Schedule III controlled substance could significantly impact the cannabis industry, particularly benefiting companies like Tilray Brands [1][2]. Company Summary - Tilray Brands' stock surged by 27.5%, closing at $13.99, following Trump's announcement, while the broader market showed mixed performance [1][2]. - The company's market capitalization stands at $1.3 billion, with a day's trading range between $10.52 and $14.54, and a 52-week range of $3.51 to $23.20 [2]. - Tilray's gross margin is reported at 20.17%, indicating the company's profitability potential despite current financial challenges [2]. Industry Summary - The potential reclassification of cannabis could lower the tax burden on cannabis companies, marking a significant step towards full legalization, which is a primary goal for investors in the sector [2][4]. - Previous administrations have considered reclassification, but the current political climate shows bipartisan support for this policy change, increasing the likelihood of its implementation [4]. - If legalization occurs, it is expected to transform Tilray's business model and overall market position, making it a potentially worthwhile investment for those with a risk tolerance and long-term perspective [4].

A shift in federal marijuana policy could be coming.Shares of Trulieve Cannabis Corp (TCNNF +14.13%) soared on Tuesday, finishing the day up 14.1%. The jump comes as the S&P 500 lost 0.3% and the Nasdaq Composite gained 0.2%.The cannabis stock is surging after President Donald Trump confirmed a report that his administration is exploring marijuana reclassification -- a shift that could reshape the cannabis industry and have an immediate impact on Trulieve's business. OTC : TCNNFTrulieve CannabisToday's Chan ...

Tilray’s jump in a broad cannabis rally shows how shifting U.S. policy signals are jolting traders, today, Dec. 16, 2025.NASDAQ : TLRYTilray BrandsToday's Change( 27.54 %) $ 3.01Current Price$ 13.94Key Data PointsMarket Cap$1.3BDay's Range$ 10.50 - $ 14.5552wk Range$ 3.51 - $ 23.20Volume47MAvg Vol9MGross Margin20.17 %Tilray Brands (TLRY +27.54%), global medical cannabis producer, closed Tuesday’s session at $13.94, up 27.54%. Trading volume reached 46.8 million shares, about 525% above its three-month avera ...

Tilray (TLRY) shares soared about 30% today after President Donald Trump said he’s “strongly” considering an executive order that will reclassify cannabis as a Schedule III drug. The expected mandate will also authorize a pilot program that will enable seniors to access cannabis products under Medicare coverage, according to media reports on Tuesday. More News from Barchart Following today’s surge, Tilray stock is up more than 100% versus its recent low set on Dec. 4. www.barchart.com What Cannabis R ...

Group 1: Cannabis Industry - MSOX, which aims for 2x daily returns of the AdvisorShares Pure US Cannabis ETF, achieved a ~94% weekly return due to anticipation of a major policy change regarding marijuana reclassification by President Trump [1] Group 2: Natural Gas Market - KOLD, providing daily inverse leveraged exposure to natural gas, returned over 52% last week as U.S. natural gas prices fell due to milder winter weather forecasts and high production levels [2] Group 3: Gold Mining Sector - GDXU, a leveraged equity fund for gold miners, returned over 17% last week, driven by a 0.25% Federal Reserve rate cut and strong central bank purchasing [3] - JNUG, which seeks to return 200% of the daily performance of the MVIS Global Junior Gold Miners Index, ranked fourth with a ~14% return [4] - NUGT, aiming for 200% of the NYSE Arca Gold Miners Index performance, also benefited from optimistic financial forecasts and strong central bank buying [5] Group 4: Banking Sector - DPST, providing 3x leveraged exposure to U.S. regional banking stocks, performed well following the Fed's quarter-point rate cut and anticipated balance sheet expansion [6] Group 5: Aerospace & Defense Industry - DFEN, which aims to triple the daily return of defense industry stocks, saw strong performance due to robust Q3 earnings from major companies and positive investor sentiment regarding proposed defense budgets for FY2026 [7] Group 6: Silver Market - AGQ, offering 2x daily long leverage to silver bullion, returned ~10%+ last week, driven by tightening inventories and sustained industrial demand [8] Group 7: Pharmaceutical Sector - PILL ETF, tracking pharmaceutical companies, returned over 9% last week, supported by reduced policy uncertainty and strong growth potential in innovative therapies [9] Group 8: Semiconductor Industry - SOXS, which inversely tracks the PHLX Semiconductor Index, achieved ~9%+ returns due to investor caution regarding valuations in AI-linked stocks following a drop in Broadcom's stock [10]

Core Insights - President Donald Trump is expected to sign an executive order to expand access to cannabis, which could significantly impact consumers and the healthcare industry [1][2] - The order may reclassify cannabis as a Schedule III drug, allowing Medicare to cover cannabis products for seniors, particularly CBD aimed at treating chronic pain and other age-related ailments [2][3] Industry Implications - The proposed changes are anticipated to facilitate research and development in the cannabis sector, as reclassification would ease regulatory barriers [5][15] - Institutional investors are likely to be attracted to the cannabis sector due to the potential for Medicare coverage, which could lead to increased valuations and liquidity in the market [5][6][19] - The U.S. cannabis production value increased by 40% last year, with the global market for cannabis-derived products projected to reach $160 billion by 2032 [18] Regulatory Landscape - The executive order is expected to define legal cannabinoids and establish a framework for FDA oversight, which could legitimize the cannabis sector for institutional investors [4][5] - The Medicare initiative, championed by financier Howard Kessler, aims to gather real-world data on the safety and outcomes of cannabinoids for seniors, bypassing traditional FDA hurdles [9][10] Market Dynamics - Stocks of cannabis companies have already seen significant increases, with Tilray Brands and Canopy Growth shares rising by 44% and 52% respectively, following rumors of the executive order [18] - A Schedule III classification could lead to more cannabis stocks being listed on major exchanges, shifting market sentiment from retail to fundamental cash flows [19][20] Competitive Landscape - The potential for Medicare coverage may attract major pharmaceutical companies, leading to increased competition and consolidation within the cannabis sector [21][23] - Smaller cannabis companies may face challenges as larger pharmaceutical firms have the resources to conduct extensive clinical trials, which could reshape the market dynamics [22][23]

Industry Overview - The cannabis sector is experiencing significant upward movement, driven by investor interest across a range of stocks following news of President Trump's potential reclassification of marijuana [1][2] - Reclassification could enhance medical research opportunities and broaden legal use cases, potentially leading to increased business activity in the medical cannabis sector [2] Company Focus: WM Technology - WM Technology (MAPS) has seen a notable stock increase of 17%, indicating strong investor enthusiasm, especially after a period of decline [4] - The company operates an online cannabis marketplace, providing e-commerce capabilities for legal cannabis purchases, which positions it well for growth if federal legalization occurs [5] - WM Technology's offerings include a Weedmaps marketplace, enhancing consumer access to local retailers and brands, which could drive future growth and improve valuation multiples [6] Financial Performance - WM Technology has reported positive earnings over the past year, although negative earnings are anticipated in the upcoming year due to slim profit margins [8] - The company's relative financial strength is appealing compared to many unprofitable peers in the cannabis sector, which has led investors to explore other sectors for growth opportunities [8]

Company Overview - EnWave Corporation is a global leader in vacuum microwave dehydration technology, headquartered in Delta, BC [3] - The company has developed a strong intellectual property portfolio and its Radiant Energy Vacuum (REV™) technology offers a scalable drying solution for the food, pharmaceutical, and cannabis industries, outperforming traditional methods in efficiency, capacity, product quality, and cost [3] Recent Developments - EnWave has granted a total of 1,410,000 incentive stock options to employees and officers, exercisable at $0.36 per share for five years, vesting in one-third increments over eighteen months [1] - Additionally, 135,000 restricted share rights were awarded to independent directors, which will vest three years from the date of the award as part of the annual compensation program [2] Strategic Partnerships - The company has over fifty partners across twenty-four countries and five continents, enabling them to create innovative snacks and ingredients while improving the quality and consistency of their products [4] - EnWave's strategy focuses on signing royalty-bearing commercial licenses with food producers to enhance drying processes, allowing for faster production and improved product attributes such as taste, texture, color, and nutritional value [5]